Pfizer Inc. is recalling 305,110 cartridges of Buprenorphine Hydrochloride Injection (0.3 mg base/mL) and Labetalol Hydrochloride Injection (5 mg/mL) sold under the Hospira label. The recall is due to a potential lack of sterility assurance caused by incomplete crimp seals on the sterile cartridge units. These injectable medications were distributed to hospitals and clinics throughout the United States and Puerto Rico.
Incomplete crimp seals can compromise the sterility of the injectable medication, potentially leading to systemic infections or other serious health complications for patients receiving the drug. No reports of adverse events or injuries related to this issue have been mentioned in the recall data.
Buprenorphine Hydrochloride Injection, 1 mL Carpuject Single-dose Cartridge
Labetalol Hydrochloride Injection, 4 mL CarpujectTM Single-dose Cartridge
If you or a family member were harmed by this recalled product, you may have legal rights. Consider consulting a consumer protection attorney to understand your options for compensation.
This is general information, not legal advice. Go Backs is not a law firm and does not provide legal services.
AI-Enhanced Content: The summary, action steps, and risk assessment on this page were generated by AI from official government recall data to improve readability. This is not legal or medical advice. Always refer to the official agency sources below for authoritative information.
Sources: FDA iRES · FDA Press Release · Raw API Response
openFDA Disclaimer: This recall information is sourced from the openFDA API. Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. Refer to the openFDA terms of service for more information.